Weekly Recap: Combination trial doses first patient and Q3 loss narrows

Janux Therapeutics, Inc. (NASDAQ:JANX) dosed the first patient in a Phase 1 trial combining JANX013 and JANX007 for metastatic prostate cancer, with more JANX007 data expected in the first half of 2027. The company posted a third-quarter 2026 loss of $21.6 million, or $0.34 per share, and had $945.7 million in cash and investments at September 30.

Previous Week Recap

• Combination Trial Doses First Patient: Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial combining JANX013 and JANX007 for metastatic prostate cancer. More JANX007 data are expected in the first half of 2027.
  • 
  • 
  • 
  3 fuentes
• Third-Quarter Loss Narrows: Janux Therapeutics (JANX) posted a third-quarter 2026 loss of $21.6 million, or $0.34 per share, versus $24.3 million a year earlier. Cash and investments totaled $945.7 million at September 30.
  • 
  • 
  • 
  3 fuentes
• Truist, Wedbush Raise Targets: Janux Therapeutics (JANX) won higher targets: Truist kept Buy and lifted its price target to $27 from $26; Wedbush kept Outperform and raised its target to $40 from $36.
  • 
  TradingView